TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants greater than or equal to 18 years of age~* Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC~* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens~* PD-L1-positive tumor status as determined by an immunohistochemistry (IHC) assay based on PD-L1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratory~* Measurable disease, as defined by RECIST version 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exception are allowed:~Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued \>7 days prior to Cycle 1, Day 1~* Central nervous system (CNS) disease, including treated brain metastases~* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome~* History of autoimmune disease~* History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening CT scan. History of radiation pneumonitis in the radiation field (fibrosis) id permitted~* Active hepatitis B or hepatitis C~* Human Immunodeficiency virus (HIV) positive~* Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metoclopramide as Treatment of Clozapine-induced Hypersalivation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years, male or female~* DSM-IV criteria for schizophrenia~* Clozapine treatment~* At least score \>2 on the Nocturnal Hypersalivation Rating Scale (NHRS)~Exclusion Criteria:~* Evidence of organic brain damage, mental retardation, alcohol or drug abuse~* Patients suffering from pheochromocytoma~* Patients suffering from Parkinson's disease

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 57 Years
- Healthy Volunteers: f

Study Arms:
- metoclopramide (Type: PLACEBO_COMPARATOR): 61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
- metocliopramide (Type: EXPERIMENTAL): 61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Field Trial of Maternal Influenza Immunization in Asia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* mid to late pregnancy~Exclusion Criteria:~* do not intend to deliver in the study area~* previous pregnancy in this study

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- influenza vaccine (Type: EXPERIMENTAL): Pregnant women assigned to the intervention group will receive one dose of seasonal influenza vaccine at the time of enrollment. The vaccine that will be given will be the current seasonal influenza recommended vaccine at the time of enrollment.
- saline placebo (Type: PLACEBO_COMPARATOR): Pregnant women assigned to the control group will receive one dose of placebo (normal saline).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 2 diabetes mellitus~* Treated with a sulfonylurea at defined doses for at least 3 months prior to screening~* BMI= 27-45 kg/m2~* HbA1c value between 7.5% and 11%~Exclusion Criteria:~* Treated with oral anti-diabetic medications other than a sulfonylurea within 3 months of screening~* Patients treated previously with AC2993~* Patients presently treated with insulin

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AC2993 5 mcg (0.02 mL) (Type: EXPERIMENTAL): Placebo, then AC2993 5 mcg, then AC2993 5 mcg
- AC2993 10mcg (0.04 mL) (Type: EXPERIMENTAL): Placebo, then AC2993 5 mcg, then AC2993 10 mcg
- Placebo 0.02 mL (Type: PLACEBO_COMPARATOR): Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
- Placebo 0.04 mL (Type: PLACEBO_COMPARATOR): Placebo 0.02 mL / Placebo 0.02 mL / Placebo 0.04 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who met the American College of Rheumatology (ACR) criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)~* Patients who completed at least 4 pain diaries within the last 7 days and the average pain score must have been ≥4, and had a score of ≥40 mm on the Visual Analogue Scale (VAS) of the SF-MPQ at screening (Visit 1) and randomization (Visit 2)~Exclusion Criteria:~* Patients with other severe pain that may confound assessment or self-evaluation of the pain associated with fibromyalgia~* Patients with any inflammatory muscle or rheumatologic disease other than fibromyalgia, active infections, or untreated endocrine disorders~* Patients with severe depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria includes:~1. Men or women ≥ 18 years~2. Subjects having IDA caused by different etiologies~3. Subjects with intolerance to oral iron therapy or a need for rapid repletion of iron stores:~4. Haemoglobin (Hb) ≤ 11 g/dL~5. Transferrin Saturation (TSAT) \< 20 %~6. S-ferritin \< 100 ng/mL~7. Willingness to participate and signing the informed consent form~Exclusion Criteria includes :~1. Anemia predominantly caused by factors other than IDA~2. Hemochromatosis or other iron storage disorders~3. Previous serious hypersensitivity reactions to any IV iron compound~4. Erythropoiesis stimulating agent (ESA) treatment~5. Prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy~6. Will require a surgical procedure that necessitated general anesthesia prior to screening or during the trial period~7. Alanine aminotransferase and/or aspartate aminotransferase \> 3 times upper limit of normal~8. Required dialysis for treatment of chronic kidney disease (CKD)~9. Alcohol or drug abuse within the past 6 months~10. Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iron isomaltoside/ferric derisomaltose (Type: EXPERIMENTAL): Administered IV
- Iron sucrose (Type: ACTIVE_COMPARATOR): Administered IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese patient (BMI\>30)~* American Society of Anesthesiologists grades II or III~* Diagnosis of impaired glucose tolerance~* Undergoing sleeve gastrectomy~Exclusion Criteria:~* Baseline glucose \> 200mg/dl~* Diagnosis of Diabetes~* Under corticosteroids treatment~* Oral hypoglycemic medication within 7 days previous surgery~* Use of insulin within 24h previous surgery~* Allergy to any drug used in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): After anesthesia induction, patients who were randomized to the Dexmedetomidine group received a bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
- 0.9% Sodium-chloride (Type: PLACEBO_COMPARATOR): After anesthesia induction, patients who were randomized to the Placebo group received a bolus and infusion of 0.9% normal saline at the same rate as the Dexmedetomidine group until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapy With an Oxytocin Adjunct for Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~• Current Major Depressive Episode~Exclusion Criteria~* Visual impairment~* Major medical illness \[A condition that is chronic and associated with impaired functioning, distress, or frequent medical intervention), in particular, subjects with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease~* Acute or chronic nasal diseases or obstruction~* Current (in the last month) use of any endocrine-relevant or psychotropic medication other than prescription antidepressants~* Current substance dependence or abuse~* Use of illicit drugs (stimulants, narcotics, psychedelics/hallucinogens, non-prescription medication) in the past 8 weeks~* Lifetime history of a psychosis (except if part of MDD) or pervasive developmental disorder~* Past or current comorbid axis-1 disorder except Dysthymia, Adjustment Disorder, Generalized Anxiety Disorder, Social Phobia, and Specific Phobia.~* Female Only: Females of child bearing potential cannot be pregnant or breastfeeding in order to participate in this study. They must not be planning to become pregnant, and must be willing to use appropriate contraception throughout the study.~* Female Only: To control for hormonal changes related to pregnancy, females will also be excluded if they have previously given birth.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Spray And Interpersonal Psychotherapy (Type: PLACEBO_COMPARATOR): Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total).
- Oxytocin Spray And Interpersonal Psychotherapy (Type: EXPERIMENTAL): Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Adults and Adolescents With Angelman Syndrome (STARS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Age 13- 49 years~2. Diagnosis of Angelman syndrome~3. Receiving a stable regimen of concomitant medications for at least 4 weeks prior to Baseline, and able to maintain these throughout the duration of the study~4. Has a caregiver capable of providing informed consent on behalf of the subject and able to attend scheduled study visits~5. Able to ingest study medication~6. Caregivers must agree not to post any subject or study information on social media~Exclusion Criteria~1. Unable to perform the study related safety and exploratory efficacy assessments, such as motor function~2. Poorly controlled seizure activity~3. Concomitant cardiovascular, respiratory, liver, renal, or hematologic diseases of a degree that would limit participation in the study~4. Pregnancy or women of child-bearing potential who are not using and acceptable method of contraception~5. Concomitant use of minocycline, levodopa, zolpidem, zaleplon, eszopiclone, ramelteon, and cannabinoid derivatives, or any other use of any investigational agent, device, and/or investigational procedure 4 weeks prior to Baseline and during the study~6. Allergy to OV101 or any excipients~7. At increased risk of harming self and/or others based on investigator assessment~8. Any condition or reason that in the opinion of the investigator makes the subject unsuitable for enrollment~9. Inability of subject or caregiver to comply with study requirements~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- OV101 regimen 1 (Type: EXPERIMENTAL): OV101 once daily
- OV101 regimen 2 (Type: EXPERIMENTAL): OV101 twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male aged ≥18 years and \<75 years.~* History of T2DM for more than 12 months.~* Inadequate glycemic control, defined as HbA1c ≥7.0% and ≤11%~* Stable anti-diabetic treatment regimen~* Renal impairment: CKD 3A~Exclusion Criteria:~* Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.~* History of diabetic ketoacidosis or hyperosmolar nonketotic coma.~* Severe uncontrolled hypertension defined as SBP ≥180 mmHg and/or Diastolic Blood Pressure (DBP) ≥110 mmHg~* Any of the following Cardiovascular (CV)/Vascular Diseases within 3 months of prior to signing the consent at visit 1:~Myocardial infarction, Cardiac surgery or revascularization(CABG/PTCA), Unstable angina, Unstable heart failure (HF), HF New York Heart Association (NYHA) Class IV,Transient ischemic attack (TIA) or significant cerebrovascular disease, Unstable or previously undiagnosed arrhythmia.~* History of any biopsy or imaging verifying intercurrent kidney disease (such as glomerular nephritis or sign of renal artery stenosis) other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis.~* Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency.~* Ongoing treatment with any SGLT2-inhibitor, GLP-1 analogue, or rapid/short acting insulins at screening.~* Participation in another clinical study with an Investigational Product (IP) during the last 30 days prior to signing the consent at visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): 10 mg Tablets, Oral, Once daily, 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pain Reduction With Intranasal Medications for Extremity Injuries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 8 years to 17 years (up to the 18th birthday)~* Presenting to emergency department with one or more extremity injuries~* Visual analog scale score 35 mm or greater~* Parent or legal guardian present and willing to provide written consent~Exclusion Criteria:~* Received narcotic pain medication prior to arrival~* Evidence of significant head, chest, abdomen, or spine injury~* Glasgow coma score less than 15 or unable to self report pain score~* Nasal trauma or aberrant nasal/airway anatomy~* Active epistaxis~* Allergy to ketamine, fentanyl or meperidine~* Non-English speaking parent and/or child~* History of psychosis~* Postmenarchal female without a urine or serum assay documenting the absence of pregnancy~* Brought in my juvenile detention center or in police custody~* Pregnancy

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Ketamine 1.5 mg/kg intranasally for one dose
- Fentanyl (Type: ACTIVE_COMPARATOR): Fentanyl 2 mcg/kg intranasally for one dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 4 to 11 years of age, inclusive, as of the Screening Visit (SV).~* A documented history of PAR to a relevant perennial allergen for a minimum of 12 months (6 months for subjects 4 to 5 years of age) immediately preceding the study Screening Visit (SV).~* A demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test.~* Other criteria apply.~Exclusion Criteria:~* History of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma (e.g., nasal piercing) or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the Screening Visit \[SV\]).~* History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, chronic sinusitis or influenza) within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-In Period.~* Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of beta-agonists and any controller drug (e.g., theophylline, leukotriene antagonists). History of intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable.~* Have any of the following conditions that are judged by the investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial.~* Other criteria apply.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- BDP Nasal Aerosol 80 mcg/day (Type: EXPERIMENTAL): BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 12-week Treatment Period.
- Placebo Nasal Aerosol (Type: PLACEBO_COMPARATOR): Placebo nasal aerosol: Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 12-week Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tetrabenazine in Chorea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* suffer from manifest HD as confirmed by genetic testing~* Meet chorea and total functional capacity scores on Unified Huntington's Disease Rating Scale~* Meet criteria on Hamilton Depression Rating Scale, Unified Parkinson's Disease Rating Scale dysphagia and dysarthria scale~* Independently ambulatory~Exclusion Criteria~* previous treatment with tetrabenazine~* unstable or serious medical or psychiatric illness~* concomitant use identified drugs~* untreated depression~* lack of caregiver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete